X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma: New drug wonders! - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma: New drug wonders!

Sep 21, 2005

Until January 2005, since India had recognized process patents, it resulted in domestic pharma companies becoming an expert in 'reverse engineering' of products. However, a major development took place in the Indian pharmaceutical market, when the product patent law was introduced with effect from January 1, 2005. This means that domestic majors will have to focus on new drug discovery research in the long term if they want to benchmark themselves against the global pharma majors. In this article, we take a look at what Indian companies are doing on the drug discovery front.

What does new drug discovery involve?
On the discovery of a molecule, the US FDA grants a patent for the molecule for a period of 20 years. New drug discovery involves various steps, which starts with the building up of a new molecule. This is followed by synthesis of the molecule and the conduct of pre-clinical testing (laboratory and animal). After this, the molecule enters the clinical trials stage, which comprises of 3 phases - I, II and III. In Phase I, studies are conducted on around 20 to 80 healthy volunteers to determine safety and dosage. In Phase II and III, a larger patient population is enrolled for the purpose of determining efficacy and side effects and also to monitor the adverse reactions of long-term use. After successful conduct of these trials, a pharma company applies for US FDA approval followed by additional post-marketing testing.

This entire process takes around 10 to 12 years of the patented life of the molecule. Which means that the remaining 8 to 10 years of the patented drug is called the 'commercial life' of the drug. Investment in launching a new product could be anywhere between US$ 400 m to US$ 800 m.

Global perspective
In the global pharmaceutical market, pharma behemoths such as Pfizer, GlaxoSmithKline, Sanofi-aventis etc. have been the pioneers in new product launches, which has resulted in them being labeled as 'innovators'. It must be noted that patented products enjoy a significant premium in terms of pricing, which more than makes up for the costs involved in drug discovery. Blockbuster drugs for instance generate revenues to the tune of US$ 1 bn annually. This translates into US$ 10 bn for the 10 years of its commercial life during which it enjoys a patent, compared to around US$ 800 m that is incurred on research!

As far as the top 10 products in the global pharmaceutical market are concerned, Pfizer, the largest pharma company in the world, leads the pack with 2 blockbuster drugs 'Lipitor' (US$ 12 bn in revenues in CY04) and 'Norvasc' (US$ 4.8 bn in revenues in CY04) under its belt. Other products in the top 10 include Merck's 'Zocor' (US$ 5.9 bn in revenues in CY04), Sanofi-aventis' 'Plavix' (US$ 5 bn in revenues in CY04), Eli Lilly's 'Zyprexa' (US$ 4.8 bn in revenues in CY04) amongst others.

Indian scenario
Domestic pharma majors such as Ranbaxy and Dr.Reddy's have been the forerunners as far as drug discovery research in India is concerned. Currently, Dr.Reddy' has 5 molecules undergoing Phase I and Phase II clinical trials. These are in the areas of oncology (anti-cancer) and metabolic disorders. Ranbaxy meanwhile has 2 molecules in Phase II clinical trials - its bronchial asthma molecule RBx 7796 and its Urology-BPH molecule RBx 2258.

Wockhardt has also identified new drug discovery as one of its growth drivers going forward. The company currently has 5 molecules in the pipeline in the anti-infectives segment, including its molecule WCK 771 undergoing Phase II clinical trials. Nicholas Piramal's anti-cancer molecule recently entered Phase I clinical trials. All these initiatives could translate into potential revenue generators in the long term.

Looking aheadů
Despite the initiatives taken by the domestic pharma industry on the drug discovery front, it is early days yet. A new patented drug from a domestic pharma company's stable will probably not see the light of day for the next 4 to 5 years or so. Also, a domestic pharma company may not have the resources to conduct the clinical trials all the way through, keeping in mind the cost involved. This means that they will have to rely on out-licensing the molecule to a global pharma major. However, despite hiccups, domestic companies have to be acknowledged for taking major strides in the area of new drug discovery. Though not in the medium term, efforts by these companies could turn into global opportunities in the long term.


Equitymaster requests your view! Post a comment on "Pharma: New drug wonders!". Click here!

  

More Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

A Simple 3-Point Investing Manifesto for You the Indian Investor(The 5 Minute Wrapup)

Apr 11, 2019

A must have checklist for every investor in the Indian stock market.

My Master Series on How to Trade Election 2019(Profit Hunter)

Apr 16, 2019

For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...

Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)

Apr 17, 2019

20% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Apr 24, 2019 11:23 AM

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS